P721: Pre-treatment frontal quantitative EEG asymmetry as a predictor of antidepressant effects of low frequency rTMS in patients with major depression

2014 ◽  
Vol 125 ◽  
pp. S247-S248
Author(s):  
J. Krstic ◽  
N. Rajsic ◽  
S.D. Milanovic ◽  
T.V. Ilic
Keyword(s):  
Major Depression ◽  
Low Frequency ◽  
Quantitative Eeg ◽  
Eeg Asymmetry ◽  
Antidepressant Effects ◽  
Pre Treatment ◽  
Low Frequency Rtms

Low-frequency rTMS inhibits the anti-depressive effect of ECT. A pilot study

2020 ◽  
Vol 32 (6) ◽  
pp. 328-338
Author(s):  
Poul Erik Buchholtz ◽  
Mahmoud Ashkanian ◽  
Simon Hjerrild ◽  
Line Kirstine Hauptmann ◽  
Torben Albert Devantier ◽  
...  
Keyword(s):  
Placebo Group ◽  
Pilot Study ◽  
Major Depression ◽  
Negative Impact ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Low Frequency ◽  
Double Blind Study ◽  
Depressant Effect ◽  
Significant Difference ◽  
Low Frequency Rtms

AbstractObjective:Low-frequency repetitive transcranial magnetic stimulation (rTMS) of the prefrontal cortex has been shown to have a statistically and clinically significant anti-depressant effect. The present pilot study was carried out to investigate if right prefrontal low-frequency rTMS as an add-on to electroconvulsive therapy (ECT) accelerates the anti-depressant effect and reduces cognitive side effects.Methods:In this randomised, controlled, double-blind study, thirty-five patients with major depression were allocated to ECT+placebo or ECT+low-frequency right prefrontal rTMS. The severity of depression was evaluated during the course using the Hamilton scale for depression (the 17-item as well as the 6-item scale) and the major depression inventory (MDI). Furthermore, neuropsychological assessment of cognitive function was carried out.Results:The study revealed no significant difference between the two groups for any of the outcomes, but with a visible trend to lower scores for MDI after treatment in the placebo group. The negative impact of ECT on neurocognitive functions was short-lived, and scores on logical memory were significantly improved compared to baseline 4 weeks after last treatment. The ECT-rTMS group revealed generally less impairment of cognitive functions than the ECT-placebo group.Conclusion:The addition of low-frequency rTMS as an add-on to ECT treatment did not result in an accelerated response. On the contrary, the results suggest that low-frequency rTMS could inhibit the anti-depressant effect of ECT.

Low-frequency rTMS to the frontal lobe increases eye-movement carryover

2021 ◽  
pp. 107895
Author(s):  
Peter J. Hills ◽  
Gizem Arabacı ◽  
Jodie Fagg ◽  
Louise Canter ◽  
Catherine Thompson ◽  
...  
Keyword(s):  
Frontal Lobe ◽  
Eye Movement ◽  
Low Frequency ◽  
Low Frequency Rtms

Some Aspects of the Psychopharmacological Activity of Maprotiline (Ludiomil®): Effects of Single and Repeated Treatments

1978 ◽  
Vol 6 (6) ◽  
pp. 421-429 ◽  
Author(s):  
A Delini-Stula ◽  
E Radeke ◽  
A Vassout
Keyword(s):  
Nervous System ◽  
Chronic Treatment ◽  
Conditioned Fear ◽  
Conditioned Avoidance ◽  
Repeated Treatment ◽  
Antidepressant Effects ◽  
The Central Nervous System ◽  
Pre Treatment ◽  
High Doses ◽  
Psychopharmacological Activity

Three different aspects of the psychopharmacological activity of the antidepressant maprotiline were investigated: its influence on serotoninergic functions the effects produced by chronic treatment its central nervous depressant and anxiolytic properties. Study of the effects of maprotiline on 5-HTP-induced head-twitch in mice pre-treated with pargyline or on hyperpyrexia in rats provided no evidence that the drug interferes with serotonin-mediated functions in the central nervous system even after quite high doses. These findings corroborate the results of extensive neurobiochemical investigations, which failed to demonstrate any influence of maprotiline on the metabolism of serotonin. Chronic studies showed that classical effects of maprotiline such as antagonism against reserpine-induced ptosis or tetrabenazine-induced catalepsy do not change in their intensity after daily administration of the drugs in a dose of 30 mg/kg p.o.for 11 days. A new component of the action of the compound, not detectable after one single dose, seems to appear, however, after repeated treatment (8 days). This effect is manifested in the restoration of conditioned avoidance behaviour after its suppression by pre-treatment with reserpine. The same effect is produced by imipramine. It is suggested that this restorative effect may be due to an additional activation of the dopaminergic nervous system and may have a bearing on the appearance of clinical antidepressant effects. Maprotiline was found to potentiate central nervous depressant effects of drugs like chlorpromazine, phenobarbitone and propranolol. This affords further confirmation that, in addition to its antidepressant qualities, it possesses sedative actions. An anxiolytic component was also demonstrated in rats in which maprotiline suppressed the conditioned, fear-induced rise in body-temperature.

Sign in / Sign up

Export Citation Format

Share Document